WT1-targeted dendritic cell vaccination as a postremission treatment to prevent or delay relapse in acute myeloid leukemia.
/in Acute Leukemia, Dendritic Cells, International Publications /von 2012-06-04 / J Clin Oncol 30, 2012 (suppl; abstr 2506)The final report of a phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with glioblastoma.
/in Dendritic Cells, Glioblastoma, International Publications /von 2012-06-02 / J Clin Oncol 30, 2012 (suppl; abstr 2084)Correlation of survival with tumor antigen expression in patients with newly diagnosed glioblastoma receiving a multi-epitope pulsed dendritic cell vaccine.
/in Dendritic Cells, Glioblastoma, International Publications /von 2012-06-02 / J Clin Oncol 30, 2012 (suppl; abstr 2087)CD40 ligand/interferon-γ matured DC immunization with gp100 antigen HLA class I A *0201 restricted peptides in patients with newly diagnosed metastatic melanoma.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2012-06-02 / J Clin Oncol 30, 2012 (suppl; abstr 2525)Adjuvant dendritic cell (DC)-based vaccine therapy of melanoma patients.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2012-06-02 / J Clin Oncol 30, 2012 (suppl; abstr 2524)Allogeneic partially HLA-matched dendritic cells (DC) as a vaccine in metastatic renal cell cancer (mRCC): Final analysis of a clinical phase I/II study.
/in Dendritic Cells, Hypernephroma, International Publications /von 2012-06-01 / J Clin Oncol 30, 2012 (suppl; abstr e15053)Dendritic/tumor fusion cells as cancer vaccines
/in Dendritic Cells, International Publications /von 2012-06-01 / Semin. Oncol. 2012 Jun;39(3):287-95[Dendritic cell-based therapeutic vaccination for acute myeloid leukemia]
/in Acute Leukemia, Dendritic Cells, International Publications /von 2012-06-01 / Bull Cancer 2012 Jun;99(6):635-42Cancer therapy and vaccination
/in Dendritic Cells, International Publications /von 2012-05-30 / J. Immunol. Methods 2012 Aug;382(1-2):1-23IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de